Sign in

    CalPIT Patel • B. Riley Securities

    Kalpit Patel is a Senior Research Analyst specializing in biotechnology at B. Riley Securities, with a primary focus on emerging companies in the oncology and immunology space. He covers a range of innovative biotech firms including Bicycle Therapeutics, Geron Corporation, Syndax Pharmaceuticals, Kymera Therapeutics, and Viridian Therapeutics, and holds a TipRanks analyst ranking with a 33% success rate and an average return of 13.5% per recommendation. Patel started his Wall Street career after several years as a pharmacist, previously serving as a director at Oppenheimer before joining B. Riley, and brings over 15 years of healthcare and finance experience. His professional credentials include an MBA from the University of Chicago Booth School of Business, a Pharm.D. from the Massachusetts College of Pharmacy, and registration as a pharmacist in Illinois.

    CalPIT Patel's questions to Kyverna Therapeutics Inc (KYTX) leadership

    CalPIT Patel's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q3 2024

    Question

    CalPIT Patel inquired about preclinical comparisons of the STAT6 program to Dupilumab, specifically regarding the atopic dermatitis ear thickness model, and asked about the human equivalent dose for a specific preclinical dose in mice.

    Answer

    Founder, President, and CEO Nellie Monofi explained that dose projections are more accurately based on dog and monkey models, which suggest a lower single-digit mg/kg dose, rather than the higher dose used in mice. She also clarified that the company focuses on TH2 biomarkers in asthma models rather than the composite ear thickness outcome.

    Ask Fintool Equity Research AI

    CalPIT Patel's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q2 2024

    Question

    CalPIT Patel from B. Riley asked for the rationale behind testing additional doses in the expanded IREC4 trials and inquired if these new doses would be outside the previously tested 50-200mg range.

    Answer

    CEO Nello Manalfi explained that adding more doses is a standard regulatory expectation for dose-ranging to establish an efficacy-safety relationship before a Phase 3 trial. This expansion is intended to accelerate the overall timeline to a registrational study. He could not comment on specific doses but confirmed they would be within the previously disclosed range.

    Ask Fintool Equity Research AI